What is your critique of the risk aversion shown by Indian venture capital funds?
Replied byKiran Mazumdar-Shaw
Founder & Executive Chairperson at Biocon
Niche: Health & Wellness
Revenue: Approx. $172 Million/month
Location: Bengaluru, Karnataka, India
Started: 1978
Indian VCs are willing to invest in safe, copycat service companies, but they avoid backing cutting-edge innovation. Pre-revenue and clinical-stage companies cannot list on Indian exchanges to raise scale-up capital, forcing our best innovators to sell their technologies to foreign buyers.
0
From the Full Interview
This answer is part of a full interview with Kiran Mazumdar-Shaw, Founder & Executive Chairperson at Biocon.
Share this Answer
Found this insight valuable? Share it with your network to help others learn from Kiran Mazumdar-Shaw's experience.
Cite This Answer
Use this answer in your research, article, or academic work
Related Answers
What was it like selling your first workout PDF on a university laptop?
By Krissy Cela
Health & Wellness
Approx. 16.6 Million USD/mo
What major contract mistake did you make at age twenty-two when launching your fitness app?
By Krissy Cela
Health & Wellness
Approx. 16.6 Million USD/mo
How did your challenging childhood as an Albanian immigrant in the United Kingdom shape your drive to win?
By Krissy Cela
Health & Wellness
Approx. 16.6 Million USD/mo
Why do you reject the idea that your employees are your family?
By Krissy Cela
Health & Wellness
Approx. 16.6 Million USD/mo
What are the four principles of impact detailed in your book?
By Adrian Gore
Health & Wellness
Approx. 400 Million/mo
What is your perspective on the potential opportunities and threats of artificial intelligence?
By Adrian Gore
Health & Wellness
Approx. 400 Million/mo
How did your father's liberal worldviews shape your early career decisions?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo